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Abstract
Background: In cluster-randomized trials (CRT), groups rather than individuals are randomized 
to interventions. The aim of this study was to present critical design, implementation, and analysis 
issues to consider when planning a CRT in the healthcare setting and to synthesize characteristics 
of published CRT in the field of healthcare epidemiology.
Methods: A systematic review was conducted to identify CRT with infection control outcomes.
Results: We identified the following 7 epidemiological principles: (1) identify design type and 
justify the use of CRT; (2) account for clustering when estimating sample size and report intraclass 
correlation coefficient (ICC)/coefficient of variation (CV); (3) obtain consent; (4) define level of 
inference; (5) consider matching and/or stratification; (6) minimize bias and/or contamination; and 
(7) account for clustering in the analysis. Among 44 included studies, the most common design 
was CRT with crossover (n = 15, 34%), followed by parallel CRT (n = 11, 25%) and stratified 
CRT (n = 7, 16%). Moreover, 22 studies (50%) offered justification for their use of CRT, and 20 
studies (45%) demonstrated that they accounted for clustering at the design phase. Only 15 studies 
(34%) reported the ICC, CV, or design effect. Also, 15 studies (34%) obtained waivers of consent, 
and 7 (16%) sought consent at the cluster level. Only 17 studies (39%) matched or stratified at 
randomization, and 10 studies (23%) did not report efforts to mitigate bias and/or contamination. 
Finally, 29 studies (88%) accounted for clustering in their analyses.
Conclusions: We must continue to improve the design and reporting of CRT to better evaluate 
the effectiveness of infection control interventions in the healthcare setting.
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In a cluster-randomized trial (CRT), clusters or groups rather than individuals are 
randomized to interventions or treatments, and outcomes are measured in all (or a 
representative sample of) individuals in the clusters or groups.1,2 CRT are well suited to 
evaluate public health, health policy, and health system interventions; they are ideal when 
the intervention carries a high risk of contamination. Contamination occurs when individuals 
randomized to different comparison groups are in close or frequent contact and may be 
influenced or “contaminated” by the intervention to which they were not randomized. This is 
likely to occur when comparing infection control and hospital epidemiology (ICHE) 
interventions within the same hospital or unit. Furthermore, when studying infectious 
diseases, individual randomization is often impractical because subjects in the 
nonintervention group may receive some protection due to the nature of transmission 
dynamics and herd immunity. Additional practical reasons for adopting this CRT design 
include simplified data collection, lower study costs, feasibility, ethical considerations, and 
often because the intervention is naturally applied at the cluster level.1
The CRT design has been well utilized in infectious disease research. Hayes et al3 reviewed 
21 papers that used a CRT design for infectious disease outcomes; however, all included 
studies described interventions applied solely in the community.3 Wolkewitz et al4 discussed 
a range of study designs, including CRT, that may be appropriate for intervention studies 
aiming to decrease hospital-acquired infections. Although the authors offer suggestions to 
improve the quality of such trials, the literature lacks specific examples of published studies 
that have used this approach in ICHE. The aim of this study is to present critical design, 
implementation, and analysis issues to consider when planning a CRT of interventions in the 
healthcare setting. Finally, we review and compare the reporting of CRT in ICHE to these 
established standards.
Methods
Design, implementation, and analysis considerations
Identification of methodological principles.—We identified 18 seminal review 
papers, expert papers, and textbooks on this topic published between 1981 and 2018. All 
authors reviewed these selected articles and relevant book chapters.1–18 Each reviewer 
described their findings in 6 in-person group discussions. Lead author L.M.O. compiled 
recurrent themes. Finally, 7 epidemiological principles were deemed most important to CRT 
in the field of ICHE.
Systematic review of published cluster-randomized trials in ICHE
Search strategy—A search of 3 databases (Ovid MEDLINE, Embase, and CENTRAL) 
was conducted in June 2017 with a medical librarian (E.L.) to identify studies in the field of 
ICHE that utilized a CRT design. No date or language restrictions were utilized during the 
search process. An iterative process was used to generate the search terms and the general 
concepts and specific terms used (for details, see Appendix 1 online).
Assessment of studies—Full-text articles were reviewed independently by 2 
investigators (L.M.O. and N.B.). To be eligible for inclusion, the study had to report an 
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infection control outcome in the healthcare setting and had to employ a CRT design. Each 
study was assessed with respect to the 7 principles agreed upon. For each study, compliance 
with each methodological principle was recorded. Disagreements in compliance scoring 
were resolved by a third investigator (A.D.H.).
Results
After searching 3 databases, 2,989 records were identified and an additional 9 records were 
added by manually searching references of included articles. After removal of duplicates and 
elimination of articles based on title and abstract review, 53 full-text articles were reviewed. 
In total, 44 articles were deemed eligible for inclusion (Fig. 1). The most common reasons 
for exclusion were (1) the study setting was not healthcare; (2) randomization was not at the 
cluster level; (3) the primary outcome was not related to hospital infection prevention; and 
(4) the article did not present original research.
The 44 articles fell into the following topic categories: health-care-associated infections (n = 
18, 40.9%), antibiotic resistance (n = 10, 7%), hand hygiene (n=8, 18.2%), environment (n = 
2, 4.5%), vaccination (n = 2, 4.5%), antibiotic stewardship (n = 2, 4.5%), and other (n = 2, 
4.5%). The number of clusters enrolled ranged from 2 to 68 hospitals or units (for details 
and full summaries of the 44 included studies, see Appendix 2 online).
The following section briefly describes each epidemiologic principle and is followed by a 
description of the compliance of an included CRT to these principles.
Principle 1: Design type and justification of use of CRT
The most basic form of CRT design is the parallel CRT; however, this design has several 
variations. Detailed descriptions, advantages, and disadvantages of each design type are 
outlined in Table 1. Authors should report the rationale for why the design chosen is most 
appropriate for their study. Some acceptable examples of design justification include the 
desire to minimize contamination bias between ICUs or floors in different study groups 
within the same facility, the recognition that a unit-level intervention would be more 
generalizable than randomly assigning the intervention at the patient-level, and the need to 
conduct a study of sufficient size with the available resources.
Systematic review findings
Of the 44 studies included in the review, 15 (34.1%) used a CRT with crossover, 11 (25.0%) 
used a parallel CRT design, 7 (15.9%) used a stratified CRT design, 4 (9.1%) used a CRT 
with stepped-wedge design, 3 (6.8%) used a matched CRT design, 2 (4.5%) used a CRT 
with crossover and multiple periods, and 2 (4.5%) used a stratified CRT design with 
crossover. Also, 22 of the included studies (50.0%) offered justification for their use of a 
CRT (Table 2). In a good example of justification for the CRT design, Huang et al (2016) 
stated that they “…chose this design to obtain results that could be generalized to the 
broadest set of hospitals, to use processes potentially adoptable by many hospitals, and to 
conduct a study of sufficient size with the available resources. Randomization of entire 
hospitals allowed us to recruit a broad array of hospitals” (see Appendix 2 online).
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Principle 2. Accounting for clustering when estimating sample size and reporting of 
intracluster correlation coefficient or coefficient of variation
The correlation and thus nonindependence that exists among individual patients in a cluster 
must be accounted for when estimating sample size for such trials, yet many studies neglect 
to consider the within-cluster and between-cluster variation as measured by the intracluster 
correlation coefficient (ICC) or coefficient of variation (CV). A review by Simpson et al5 of 
primary prevention trials showed that only 4 studies (19%) accounted for between-cluster 
variation in their sample size or power calculation. ICC measures the degree of similarity 
among outcomes within a cluster.6 Generally, the higher the ICC, the more similarity that 
exists within clusters resulting in a loss of precision estimating effect of intervention. 
Therefore, standard approaches for estimating sample size that do not consider clustering 
may increase the probability of a type II error, meaning that the study will be underpowered.
1
In some studies, clustering may arise at >1 level; therefore, 2 ICCs should be defined, for 
example, when an ICU within a hospital and the hospital itself are randomized. Variation 
exists among hospitals in addition to variation among ICUs within a hospital. An additional 
source of variance arises when the crossover design is used and each cluster receives the 
intervention in a separate period of time. In this case, it is important to account for period 
variance.7
Cluster randomization is less statistically efficient than randomizing individuals. Increasing 
the number of clusters enrolled in a CRT has a greater impact than increasing the number of 
individuals enrolled within each cluster on statistical power.6,8 Therefore, many investigators 
choose to enroll a subsample of individuals within each cluster. The numbers of individuals 
needed to enroll per cluster depends largely on the underlying value of the ICC9 and the 
anticipated effect size. A paper by Rutterford et al10 provides detailed guidance on how to 
estimate sample sizes for CRT.
Systematic review findings
As shown in Table 2, 20 of 33 studies (60.6%) in which inference was made at the individual 
level accounted for clustering at the design phase when estimating sample size and power 
for their study. In addition, 15 studies (45.5%) reported the ICC, CV, or design effect. These 
values ranged from 0.005 to 0.38.
Principle 3. Consent
Randomization of groups rather than individuals presents unique ethical considerations. It 
may be appropriate for key decisions makers to act as surrogates for a community or cluster 
and consent to randomization.11 For example, nurse managers may consent on behalf of 
their unit to participate in an intervention trial with the outcome of hand hygiene adherence. 
Although ethical approval may be given at the cluster level, the refusal of an individual 
patient or healthcare worker (HCW) to participate in a study must be Epidemiology 
respected. It can be logistically difficult and perhaps unfeasible to obtain individual consent 
from large clusters.12
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Systematic review findings
Overall, 15 studies (34%) obtained waived consent, 14 (32%) did not report how they dealt 
with consent, 8 (18%) reported that they obtained consent from individuals, and 7 (16%) 
reported consent at the cluster level. A good example of consent at the cluster level is 
described by Fuller et al (2012) where ward managers, infection control nurses, and ward 
coordinators consented on behalf of all other staff members to participate in a hand hygiene 
study (see Appendix 2 online).
Principle 4. Level of inference
In epidemiology, inference refers to the statistical process of generalizing from sample data 
to a wider population. A key property of CRT is that inferences are frequently intended to 
apply at the individual level, whereas randomization occurs at the cluster or group level. For 
example, to evaluate the effectiveness of a hand hygiene improvement intervention, 
researchers may choose randomization to occur at the unit level but adherence with hand 
hygiene recommendations to be assessed for each individual HCW within each cluster.
It is important to correctly identify whether the unit of inference will be at the individual or 
cluster level early in the planning stage of the trial. If randomization, variable collection, and 
analysis are all conducted at the cluster level, then sample size estimates and statistical 
analyses can be done as a standard randomized controlled trial.6
Systematic review findings
Of the 44 included studies, the level of inference was considered at the individual level for 
32 studies (72.7%) and at the cluster level for 11 studies (25.0%). In 1 study (2.3%), 
randomization, variable collection, and analysis were conducted at both the individual and 
cluster levels.
Principle 5. Matching and/or stratification
Although matching can provide a simple method to consider potential confounders at the 
design stage, this approach may be overused and effective matching may be especially 
difficult in smaller studies.13 Recruiting a large number of pairs provides statistical 
advantage only if the pairs represent different levels of baseline risk.1 Furthermore, if a 
single member of a matched pair drops out of the study, this requires that both members of 
the pair be dropped from the analyses, thereby possibly rendering the study underpowered. 
Matching in a CRT should therefore be adopted with caution. Stratification is another 
approach that is commonly used to ensure that there is balance in cluster size per 
intervention and control groups within strata.1,6
Systematic review findings
Overall, 17 studies (38.6%) matched or stratified at time of randomization, whereas 27 
(61.4%) did not employ either of these techniques. Examples of matching variables used 
included geographic region, rate of outcome, type of ICU, number of ICU or hospital beds, 
and hospital volume. A good example of appropriate matching can be found in the BUGG 
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study published by Harris et al (2013), in which ICUs were paired and matched based on 
baseline MRSA and VRE acquisition rates (see Appendix 2 online).
Principle 6. Reducing the potential for bias and/or contamination
The goal of randomization is to minimize bias or to ensure that the baseline characteristics 
of the various clusters are balanced in different intervention groups. When conducting a 
study in the healthcare setting, the “transmission” of behaviors, attitudes, or knowledge 
among HCWs who are in regular contact can result in similar responses. This is sometimes 
referred to as a “herd effect.” Similarly, the Hawthorne effect can be an issue in CRT. 
Intervention groups may benefit from increased attention and not solely from the 
intervention itself. To mitigate this, instead of studying only the standard of care in the 
control group, researchers may consider using a “minimal intervention” or “active controls.” 
Puffer et al14 found potential recruitment bias in 14 of 36 CRT reviewed (14%). There are 
several additional ways to reduce the potential for bias and contamination when conducting 
a CRT in the field of ICHE. For example, the study can be implemented in areas where 
clusters are distinct and well separated, and control-group clusters can be used that are 
external to the experimental trial; randomizing different locations within a hospital to control 
and intervention groups may be problematic. If a crossover design is used, it may be 
appropriate to employ multiple crossover periods and a wash-out period that is long enough 
to ensure that there are no residual effects. Furthermore, employing the CRT with crossover 
design is only appropriate if there is no carryover, which is rare in ICHE.
Systematic review findings
Overall, 34 studies (77.3%) reported some efforts to reduce the potential for bias and/or 
contamination. Most common were the use of a baseline period and the use of a wash-out 
period. Of all 44 studies, 7 (16.5%) reported the use of a baseline period, and 7 of 19 studies 
that used a crossover design (36.8%) reported using a wash-out period, which ranged from 2 
to 4 weeks. Also, 3 studies (6.8%) specifically reported that the intervention was 
implemented in clusters that were distinct and well separated. A good example of efforts to 
reduce bias and contamination are described by de Smet et al (2009) (see Appendix 2 
online). The authors ensured that the order of digestive tract decontamination regimens were 
randomly assigned, that the person in charge of randomization was blinded to ICU identity, 
and that the study periods were preceded by a wash-in and/or wash-out month.
Principle 7. Accounting for clustering in the analysis
The lack of independence among individual patients or HCWs in the same cluster, creates 
special methodological challenges. If between-cluster variation is not taken into account, a 
false claim of statistical significance may result via an increase in the probability of a type I 
error. Therefore, a main concern in CRT is internal validity. Many CRT fail to account for 
between-cluster variation at both the design and analysis stage. The aforementioned review 
by Simpson et al of primary prevention trials showed that only 12 (57%) accounted for 
clustering in their analyses.5
To obtain unbiased estimates of the effect of the intervention, analyses must be based on 
data from all cluster members or must be based on a random subsample of cluster members. 
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It is necessary to decide whether to model the predictor variables as either fixed or random.
15
 In many CRT, the cluster effect is modeled as random and the intervention effect is 
modeled as fixed. Several different approaches can be used to ensure that all comparative 
analyses allow for the clustered nature of the data and that correct confidence intervals and 
type I error rates are calculated. For example, a generalized estimating equation (GEE) can 
accommodate cluster-level and individual-level covariates. Similarly, proportional-hazards 
models with shared frailties can account for clustering within hospitals.
Systematic review findings
Of 33 studies, 29 (87.9%) accounted for clustering in their analyses. Only those in which the 
level of inference was the individual were included in the denominator of this calculation. 
Most of these studies used mixed-effects regression models or fixed-effects regression 
models to account for clustering. Rupp et al (2008) explain how they accounted for 
clustering at the analysis stage as follows: “…GEE were used to analyze hand hygiene 
adherence rates over time and their relationship to job category and hand gel availability, 
appropriately accounting for the potential correlation among observations” (Appendix 2 
online).
Discussion
We have presented 7 critical design, implementation, and analysis principles to consider 
when planning a CRT of infection prevention and control interventions in the healthcare 
setting (summarized in Table 3). Adherence to these principles was variable among 44 ICHE 
studies identified by a systematic review, which suggests the need for more systematic 
reporting in this field. Notably, we did not identify any published studies in this field that 
employed a factorial or fractional factorial design. As shown in Table 1, each design type 
has advantages and disadvantages. The most appropriate design depends on the setting and 
research question. Many studies (82%) reported accounting for clustering during their 
analyses; however, <50% reported accounting for clustering when estimating sample size, 
and only 34% reported the ICC or CV that they used to do so. Reporting of these design 
effects is necessary to provide references for what constitutes a reasonable estimate for 
similar interventions and outcomes.
The aforementioned review, conducted in 2000, assessed CRT of infectious disease 
outcomes and identified only 21 such studies.3 Our study included twice as many published 
articles, even when narrowed to a small subset of infectious diseases research. This 
illustrates the emergence of this design in research in recent years. Another recent review 
examined CRT in the general practice setting that included a patient-relevant outcome.16 
This article suggests that when studies of complex interventions (like those in the healthcare 
setting) are poorly designed and implemented, they often do not yield useful information. 
Because CRT are complex and costly, methodological rigor is of utmost importance.
In addition to the epidemiological principles presented here within the context of ICHE 
research, several tools are available to improve CRT. The Consolidated Standards of 
Reporting Trials (CONSORT) checklist provides evidence-based recommendations for 
reporting randomized trials and encourages authors to report their work in a transparent and 
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standardized manner. CONSORT now offers an official extension for CRT,17 and researchers 
are encouraged to refer to this. Similarly, Hemming et al18 present power and precision 
curves that can be used as guidance when determining cluster size and Reich et al19 provide 
a framework and R code for estimating power via simulation with or without 1 or more 
crossover periods. Finally, Caille et al20 developed a graphical tool that identifies potential 
bias in CRT by depicting the time sequence of steps and blinding status.
In conclusion, the CRT design is used often in the field of ICHE, yet adherence to critical 
epidemiological principles remains suboptimal. Conduct and reporting of methodologically 
rigorous evaluations of infection prevention and control outcomes in the healthcare setting 
can inform best practice and policy.
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Fig. 1. 
PRISMA flow diagram* of search results. *From: Moher D, Liberati A, Tetzlaff J, Altman 
DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses: The PRISMA Statement.
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